| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) (NCT07621718) | Revolution Medicines, Inc. | 2026-05-22 |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (NCT07491445) | Revolution Medicines, Inc. | 2026-03-09 |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors (NCT07397338) | Revolution Medicines, Inc. | 2026-01-30 |
| Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors (NCT07349537) | Revolution Medicines, Inc. | 2026-01-08 |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (NCT07252232) | Revolution Medicines, Inc. | 2025-12-15 |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) (NCT06881784) | Revolution Medicines, Inc. | 2025-05-06 |
| Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (NCT06625320) | Revolution Medicines, Inc. | 2024-10-16 |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (NCT06445062) | Revolution Medicines, Inc. | 2024-05-24 |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC (NCT06162221) | Revolution Medicines, Inc. | 2024-01-18 |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors (NCT06128551) | Revolution Medicines, Inc. | 2023-11-14 |
| Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors (NCT06040541) | Revolution Medicines, Inc. | 2023-09-07 |
| Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (NCT05462717) | Revolution Medicines, Inc. | 2022-09-19 |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (NCT05379985) | Revolution Medicines, Inc. | 2022-05-31 |
| Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies (NCT05054725) | Revolution Medicines, Inc. | 2021-12-30 |
| Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors (NCT04774952) | Revolution Medicines, Inc. | 2021-04-07 |
| Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC (NCT03989115) | Revolution Medicines, Inc. | 2019-07-02 |
| Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors (NCT03634982) | Revolution Medicines, Inc. | 2018-09-28 |